Pneumococcal vaccine and opsonic pneumococcal antibody

Joon Young Song, M. Allen Moseley, Robert L. Burton, Moon H. Nahm

    Research output: Contribution to journalReview articlepeer-review

    110 Citations (Scopus)


    Streptococcus pneumoniae is a major human pathogen responsible for the majority of bacterial pneumonia cases as well as invasive pneumococcal diseases with high mortality and morbidity. Use of conjugate vaccines targeting the pneumococcal capsule has dramatically reduced the incidence of invasive diseases, and there are active efforts to further improve the conjugate vaccines. However, in children new pneumococcal vaccines can no longer be tested with placebo-based clinical trials because effective vaccines are currently available. Thus, vaccine studies must depend on surrogate markers of vaccine efficacy. Although traditional antibody levels (e.g., ELISA) are useful as a surrogate marker of protection, they have limitations, and a bioassay measuring the capacity of antibodies to opsonize pneumococci has been developed. This opsonophagocytosis assay (OPA) replicates the in vivo mechanism of antibody protection and should therefore better reflect protection by vaccine-induced antibodies. Technical improvements of OPA have made this bioassay rapid, multiplexed, and practical for analyzing small samples including those from children. Strong correlations between ELISA and OPA have been observed in many studies of young children. However, poor correlations have been found in some important clinical situations (such as determination of protection by cross-reactive antibodies) and populations (such as elderly adults and immunodeficient patients). In these settings, OPA has become a useful supplementary measure of pneumococcal vaccine immunogenicity. Current efforts to standardize OPA will further expand its uses.

    Original languageEnglish
    Pages (from-to)412-425
    Number of pages14
    JournalJournal of Infection and Chemotherapy
    Issue number3
    Publication statusPublished - 2013 Jun


    • Immunogenicity
    • Opsonophagocytic killing assay
    • Pneumococcal vaccine
    • Streptococcus pneumoniae

    ASJC Scopus subject areas

    • Microbiology (medical)
    • Pharmacology (medical)
    • Infectious Diseases


    Dive into the research topics of 'Pneumococcal vaccine and opsonic pneumococcal antibody'. Together they form a unique fingerprint.

    Cite this